ICAD strategy in cancer detection, shares with muted Nasdaq trading profile
Published on 06/22/2026 at 18:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-22, 18:31.
ICAD (US45071L1098) continues to trade on the Nasdaq in the medical technology segment with a market capitalization a little above 100 million dollars, according to recent quote data. Recent MarketBeat data on ICAD The company remains focused on oncology imaging and therapy software against larger peers such as Hologic and GE HealthCare.
What the latest figures show
For the last reported full year ICAD posted a trailing twelve-month net loss of about 5.6 million dollars and a negative earnings per share of 0.19 dollars, according to MarketBeat compilation of filings. MarketBeat company overview That translates into a price/earnings ratio that remains not meaningful on standard metrics.
The firm employs around 140 people and is classified in the broader computer and technology sector with a focus on medical equipment and cancer detection software. MarketBeat industry classification Its most recent quarterly report in mid-May 2025 marked the last earnings update captured on several data platforms, underlining the relatively low analyst coverage compared with larger S&P 500 healthcare names.
Analyst and trading profile
MarketBeat currently flags ICAD with no active consensus rating or explicit Wall Street price target, contrasting with the dense coverage typical for bigger Nasdaq-100 medtech stocks. MarketBeat rating snapshot Average daily volume stands at roughly 370,000 shares, indicating modest liquidity for a Nasdaq-listed medical technology name.
The shares have recently traded in a 52-week range between about 3.17 and 4.02 dollars, with a recent spot level just under 4 dollars per share on Nasdaq. MarketBeat price range data At this level the implied market capitalization sits near 106 million dollars, keeping ICAD firmly in the small-cap bracket for U.S. investors.
All news and data on the ICAD shares
Further regulatory filings, price history and corporate news help investors assess the small-cap medtech profile of ICAD in more detail.
How ICAD makes its money
ICAD generates revenue primarily from cancer detection and therapy software, including artificial intelligence tools for breast imaging and radiation treatment optimization, as described in its corporate materials. ICAD company website The solutions are sold to hospitals and imaging centers, often as software licenses and service contracts.
Where the stock trades now
The ICAD shares (US45071L1098) recently traded on Nasdaq at around 3.87 dollars as of 2026-06-22, 15:30 Eastern Time, based on MarketBeat quote consolidation. MarketBeat intraday quote
Key data on the ICAD shares
- Company: iCAD, Inc.
- ISIN: US45071L1098
- WKN: 924584
- Ticker: ICAD
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 15:30): 3.87 USD
- Market cap: 106.31 million USD (as of 2026-06-22)
- Sector / industry: Health Care / Medical Technology and Software
- Index membership: none of the major headline indices (such as S&P 500 or NASDAQ-100)
- Next earnings date: not officially scheduled
This text is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
